Table 4:

Overall survival of patients (IC vs. HMA) by proportional hazards model using alloSCT as a time-dependent covariate since diagnosis. AML: Acute myeloid leukemia; AML-MRC: AML with myelodysplasia-related changes; CCI: Charlson Comorbidity Index; CI: confidence interval; CK: complex karyotype; ECOG-PS: Eastern Cooperative Oncology Group performance status scores; HMA: Hypomethylating agent; HR: hazard ratio; IC: Intensive chemotherapy; MK: monosomal karyotype; s-AML: secondary AML; t-AML: therapy related AML

	No additional adjustment	Adjusted for ECOG, CCI, and age
	HR (95% CI)
Overall population	0.75 (0.55–1.02)	0.84 (0.60–1.16)
Age group (yrs):
60–64	0.90 (0.33–2.42)	1.23 (0.40–3.79)
65–69	1.06 (0.55–2.06)	1.35 (0.67–2.70)
70–95	0.67 (0.43–1.03)	0.77 (0.48–1.22)
Type of AML:
s-AML	0.96 (0.58–1.59)	1.17 (0.65–2.10)
t-AML	0.56 (0.33–0.97)	0.46 (0.25–0.87)
AML-MRC	0.82 (0.56–1.20)	0.93 (0.63–1.38)
Cytogenetics:
CK+MK−	0.37 (0.19–0.75)	0.50 (0.22–1.11)
CK+MK+	2.00 (1.08–3.70)	2.57 (1.26–5.22)